Adapting UK Clinical Practise in Chronic Myeloid Leukaemia in Chronic Phase to Contemporary Management Recommendations: The ADAPT 2.0 Survey

ABSTRACT Objective Chronic myeloid leukaemia in chronic phase (CML‐CP) treatment recommendations have changed substantially in recent years. The ADAPT 2.0 survey aimed to provide an updated understanding of CML‐CP management in the UK. Methods This healthcare professional (HCP) survey, conducted between December 2023 and June 2024, assessed treatment goals, choice of tyrosine kinase inhibitors (TKIs), unmet needs and approaches to treatment‐free remission (TFR). Results UK CML‐CP practise is generally aligned with the contemporary guidelines for CML management. Key treatment goals were major molecular response (54%–77% across treatment lines) and deep molecular response (5%–46%). The main factors influencing first‐line (1 L) TKI selection were treatment guidelines (97%), comorbidities (90%) and TFR as a treatment goal (82%). Therapy switch after one warning European LeukemiaNet (ELN) 2020 response was rare (10% vs. 56% in patients with > 1 warning response and 100% in failure response). BCR::ABL1 mutation analysis was less common after one warning response versus > 1 warning response (54% vs. 82%). TKI toxicity, resistance, intolerance and T315I mutation management were key unmet needs in later treatment lines; achieving and maintaining TFR were key unmet needs in 1 L. Conclusion The ADAPT 2.0 survey highlights potential areas of improvement in current CML‐CP management in the UK.